检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:唐慧敏 TANG Huimin(Department of Gastroenterology,Liaoyang Central Hospital,Liaoyang,Liaoning 111000,China)
机构地区:[1]辽阳市中心医院消化内科,辽宁辽阳111000
出 处:《中国医药指南》2025年第4期88-90,共3页Guide of China Medicine
摘 要:目的探讨莫沙必利+应用氟哌噻吨美利曲辛药物对功能性消化不良患者治疗的价值。方法选取2022年4月至2023年4月就诊于辽阳市中心医院功能性消化不良患者90例,通过随机数字表法,把患者划分为观察组与对照组,每组45例。对照组患者采用单一药物治疗,仅用莫沙必利,观察组患者采用联合用药治疗,同时用莫沙必利和氟哌噻吨美利曲辛,比较两组治疗效果、胃排空情况、症状变化情况。结果经过治疗,两组出现反酸、腹胀、很容易饱状况均有所减轻,观察组的减轻幅度大于对照组(P<0.05)。经过治疗,观察组的胃排空率高于对照组(P<0.05)。比对两组疗效,观察组的疗效优于对照组(P<0.05)。结论治疗功能性消化不良患者,选择莫沙必利与氟哌噻吨美利曲辛作为共同治疗药物,可以增加胃排空率。Objective To explore the value of Moxapride combined with fluperthixol melitracen in the treatment of patients with functional dyspepsia.Methods A total of 90 patients with functional dyspepsia admitted to Liaoyang Central Hospital from April 2022 to April 2023 were selected and divided into observation group and control group by random number table method,with 45 cases in each group.The control group was treated with single drug and only moxapride,while the observation group was treated with combined drug and moxapride and flupentixol melittrix.The therapeutic effect,gastric emptyl and symptom changes of the two groups were compared.Results After treatment,acid reflux,abdominal distension and easy satiety were alleviated in both groups,and the reduction in observation group was greater than that in control group(P<0.05).After treatment,the gastric emptying rate of observation group was higher than that of control group(P<0.05).Compared with the two groups,the curative effect of the observation group was much better than that of the control group(P<0.05).Conclusions In the treatment of patients with functional dyspepsia,Moxapride and haloperthixol melitracen are selected as cotreatment drugs,which can increase the gastric emptying rate.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:3.144.135.25